NCT06657768

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 128 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 45 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.

Conditions

• Alzheimer Disease
• Healthy

Interventions

Type	Name	Description
DRUG	LY4006895	Administered IV
DRUG	Placebo	Administered IV

Timeline

• Start date: 2024-10-29
• Primary completion: 2027-07-01
• Completion: 2027-07-01
• First posted: 2024-10-24
• Last updated: 2026-03-27

Locations

9 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study